RIGEL PHARMACEUTICALS INC's ticker is RIGL and the CUSIP is 766559603. A total of 154 filers reported holding RIGEL PHARMACEUTICALS INC in Q1 2021. The put-call ratio across all filers is 1.04 and the average weighting 0.1%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q4 2022 | $484 | -99.8% | 322,500 | +61.2% | 0.76% | +153.3% |
Q3 2022 | $236,000 | -9.2% | 200,000 | -13.0% | 0.30% | -1.9% |
Q2 2022 | $260,000 | -35.6% | 230,000 | +70.4% | 0.31% | -51.7% |
Q1 2022 | $404,000 | -19.8% | 135,000 | -28.9% | 0.64% | -1.7% |
Q4 2021 | $504,000 | +13.3% | 190,000 | +55.1% | 0.65% | +8.2% |
Q3 2021 | $445,000 | +28.2% | 122,500 | +53.1% | 0.60% | +25.8% |
Q2 2021 | $347,000 | +12.7% | 80,000 | -11.1% | 0.48% | +37.1% |
Q1 2021 | $308,000 | -17.0% | 90,000 | -15.1% | 0.35% | -44.5% |
Q4 2020 | $371,000 | -52.4% | 106,009 | -67.4% | 0.63% | -63.0% |
Q3 2020 | $780,000 | +88.9% | 325,000 | +44.1% | 1.70% | +51.2% |
Q2 2020 | $413,000 | +17.3% | 225,500 | 0.0% | 1.12% | -8.9% |
Q1 2020 | $352,000 | -27.1% | 225,500 | 0.0% | 1.23% | -23.6% |
Q4 2019 | $483,000 | +13.6% | 225,500 | -0.9% | 1.61% | +31.3% |
Q3 2019 | $425,000 | -30.4% | 227,500 | -2.8% | 1.23% | +159.7% |
Q2 2019 | $611,000 | -20.8% | 234,000 | -22.0% | 0.47% | +20.4% |
Q1 2019 | $771,000 | +28.9% | 300,000 | +15.4% | 0.39% | +2.9% |
Q4 2018 | $598,000 | +54.1% | 260,000 | +114.9% | 0.38% | +116.5% |
Q3 2018 | $388,000 | -23.8% | 121,000 | -32.8% | 0.18% | -9.3% |
Q2 2018 | $509,000 | +15.2% | 180,000 | +44.0% | 0.19% | +17.6% |
Q1 2018 | $442,000 | -52.5% | 125,000 | -47.9% | 0.16% | -53.5% |
Q4 2017 | $931,000 | +83.3% | 239,900 | +20.0% | 0.36% | +96.1% |
Q3 2017 | $508,000 | -15.5% | 200,000 | -9.1% | 0.18% | -36.0% |
Q2 2017 | $601,000 | +6.7% | 220,000 | +29.4% | 0.28% | +11.9% |
Q1 2017 | $563,000 | +56.0% | 170,000 | +12.1% | 0.25% | +24.0% |
Q4 2016 | $361,000 | +10.4% | 151,686 | +70.4% | 0.20% | -0.5% |
Q3 2016 | $327,000 | +72.1% | 89,000 | +4.7% | 0.20% | +101.0% |
Q2 2016 | $190,000 | -54.3% | 85,000 | -57.5% | 0.10% | -15.7% |
Q1 2016 | $416,000 | -45.1% | 200,000 | -20.0% | 0.12% | -53.1% |
Q4 2015 | $758,000 | +22.7% | 250,000 | 0.0% | 0.26% | -2.6% |
Q3 2015 | $618,000 | -22.9% | 250,000 | 0.0% | 0.26% | -26.8% |
Q2 2015 | $802,000 | +12.3% | 250,000 | +25.0% | 0.36% | -8.1% |
Q1 2015 | $714,000 | +4.8% | 200,000 | -33.3% | 0.39% | -6.6% |
Q4 2014 | $681,000 | – | 300,000 | – | 0.42% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
CM Management, LLC | 1,500,000 | $1,620,000 | 1.72% |
Soleus Capital Management, L.P. | 14,803,015 | $15,987,256 | 1.48% |
ARMISTICE CAPITAL, LLC | 17,136,000 | $18,506,880 | 0.28% |
SPHERA FUNDS MANAGEMENT LTD. | 1,228,126 | $1,326,376 | 0.24% |
GSA CAPITAL PARTNERS LLP | 971,441 | $1,049 | 0.09% |
NJ State Employees Deferred Compensation Plan | 200,000 | $216,000 | 0.03% |
Providence Wealth Advisors, LLC | 27,500 | $29,013 | 0.03% |
OCONNOR, A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS (LLC) | 1,151,765 | $1,243,906 | 0.03% |
XTX Topco Ltd | 164,238 | $177,377 | 0.03% |
JACOBS LEVY EQUITY MANAGEMENT, INC | 3,369,076 | $3,638,602 | 0.02% |